Latest SAR Stories
RIYADH, Saudi Arabia, Aug. 6, 2012 /PRNewswire/ -- Etihad Etisalat (Mobily) and IBM (NYSE: IBM) have announced a 5-year agreement worth approximately $280 million to provide comprehensive IT solutions for the Saudi Arabian company. (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO ) As the fastest growing telecommunications company in Saudi Arabia, Mobily has experienced an explosion in demand from the growing number of subscribers using mobile devices, and needed to...
BRISBANE, Calif., March 5, 2012 /PRNewswire/ -- SARcode Bioscience, Inc., a privately held biopharmaceutical company, announced today that it has completed patient enrollment in their first pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution. SAR 1118 is a first-in-class small-molecule integrin antagonist that inhibits T-cell inflammation by blocking the binding of two key surface proteins (LFA-1 and ICAM-1) that mediate the chronic inflammatory cascade...
CHICAGO, Oct. 25, 2011 /PRNewswire/ -- 4G World -- Alcatel-Lucent (Euronext Paris and NYSE: ALU) has once again been recognized for its leadership in the mobile backhaul market, with a new report by leading industry analyst firm Infonetics Research. In the report, Mobile Backhaul Equipment and Services - Biannual Worldwide and Regional Market Share, Size, and Forecasts, Alcatel-Lucent is cited as the leading vendor in the Ethernet cell site gateway and Ethernet mobile backhaul router market...
Small satellite manufacturer Surrey Satellite Technology Limited (SSTL) has today announced completion of the development phase of its new low-cost Synthetic Aperture Radar (SAR) satellite system. Called NovaSAR-S, the system offers customers coverage of any spot on Earth in all conditions – seeing through cloud cover across both day and night. The 400-kg NovaSAR-S design combines SSTL’s flight-proven SSTL-300 platform with an innovative S-band SAR payload, developed in collaboration...
BRISBANE, Calif., Sept. 14, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution. (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO ) SAR 1118 is a first-in-class molecule that inhibits T-cell inflammation by blocking the binding of two key cellular surface proteins (LFA-1 and ICAM-1) that...
BRISBANE, Calif., July 18, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners. (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO ) "We believe that SARcode is uniquely positioned to...
BRISBANE, Calif., May 3, 2011 /PRNewswire/ -- SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida. SAR...
BRISBANE, Calif., March 24, 2011 /PRNewswire/ -- SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1-May 5, 2011, in Fort Lauderdale, Florida. SAR 1118 is an investigational novel small-molecule topical therapy that inhibits T-cell mediated inflammation, a key component of dry eye syndrome. (Logo:...
SAN FRANCISCO, Feb. 14, 2011 /PRNewswire/ -- SARcode Corporation has named Todd Creech as Chief Financial Officer and Vice President of Business Development effective February 1, 2011. Creech has been fulfilling both positions as a consultant to SARcode since November 2010. (Photo: http://photos.prnewswire.com/prnh/20110214/FL47222LOGO ) "Todd comes to SARcode with a wealth of experience in finance and leadership roles and has demonstrated great success in helping to drive positive...
SAN FRANCISCO, May 3 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca). The study results were presented at the Dry Eye Summit meeting on April 30th in Fort Lauderdale,...
